Jonathan Young - Jan 7, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Jan 7, 2022
Transactions value $
$17,063
Form type
4
Date filed
1/11/2022, 03:40 PM
Previous filing
Dec 10, 2021
Next filing
Sep 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $17.1K +27.7K +20.47% $0.62* 163K Jan 7, 2022 Direct
holding AKRO Common Stock 20K Jan 7, 2022 By EA Irrevocable Trust F1
holding AKRO Common Stock 20K Jan 7, 2022 By CM Irrevocable Trust F1
holding AKRO Common Stock 20K Jan 7, 2022 By JL Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Employee Stock Option (Right to Buy) Options Exercise $0 -26.3K -100% $0.00* 0 Jan 7, 2022 Common Stock 26.3K $0.62 Direct F2
transaction AKRO Employee Stock Option (Right to Buy) Options Exercise $0 -1.45K -1.54% $0.00 92.8K Jan 7, 2022 Common Stock 1.45K $0.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.
F3 Shares vested and became exercisable in equal monthly installments for a period of 48 months following October 1, 2018.